Our library of drug research abstracts drawn from the medical literature is updated on a regular schedule, and you can be assured that new lumigan research articles will be listed here shortly after becoming available to us.
Related Sponsors
Medical research on lumigan
[Considerations about administration angle of prostaglandin analogs.]
Arq Bras Oftalmol. 2008 Sep-Oct; 71(5): 684-8
Estacia P, Tognon T
PURPOSE: To investigate if there is any difference in volume and drop weight of prostaglandin analogs when adopting drip angles of 45 masculine and 90 masculine, regarding a horizontal line. METHODS: An experimental study was conducted using the follow ophthalmic solutions: latanoprost, travoprost and bimatoprost. In this study the ophthalmic solutions were dripped according to an angle of 45 masculine or 90 masculine. Prostaglandin analogs were chosen due to their common use in ophthalmology and their cost. The first drop and other ten drops were weighed, alternating the drip angle (45 masculine or 90 masculine). Statistical analysis was done with SPSS(R) 12.0 (Microsoft), using quantitative comparisons with the ANOVA test. An odds value (P) below 0.001 was considered a statistical significant difference. RESULTS: We verified differences in weight and size of the travoprost and bimatoprost drops instilled at 45 masculine and 90 masculine. The drip at 45 masculine produces a smaller drop of travoprost (P
Flare-up rates with bimatoprost therapy in uveitic glaucoma.
Am J Ophthalmol. 2008 Dec; 146(6): 876-82
Fortuna E, Castañeda-Cervantes RA, Bhat P, Doctor P, Foster CS
PURPOSE: To evaluate the rate of flares in patients with uveitic glaucoma treated with topical bimatoprost and to assess its effect on intraocular pressure (IOP) in this subset of patients. DESIGN: Retrospective case series. METHODS: All patients seen at one subspecialty uveitis practice with history of uveitic glaucoma treated with topical bimatoprost were identified and the data collected, which included onset, type, duration of uveitis, onset of secondary glaucoma, and previous therapies for glaucoma. The time of onset of bimatoprost therapy, the IOP, and flare-up rate before and after initiation of treatment with bimatoprost were recorded at one week and one, three, and six months of follow-up. RESULTS: Of the 42 patients (59 eyes) identified, 12 patients had used other topical lipid agents, which were replaced by bimatoprost. Twenty-three patients had not used any lipid agents and bimatoprost was added to their existing antiglaucoma regimen. Seven patients were newly diagnosed with uveitic glaucoma and were commenced with topical bimatoprost. The rate of uveitis flares while on other antiglaucoma therapy was 52 per 100 person-years follow-up, while on bimatoprost therapy it was 32.4 per 100 person-years follow-up (P = .206). The mean IOP prior to bimatoprost therapy was 27 +/- 13.2 mm Hg and after initiation of topical bimatoprost was 15 +/- 5.5 mm Hg at the end of six months (P = .0008). CONCLUSION: These data suggest that bimatoprost is an effective IOP-lowering agent in patients with uveitic glaucoma in whom the uveitis is controlled on immunomodulatory therapy, and it does not increase the rate of flares of uveitis in these patients.
Effect of bimatoprost on intraocular pressure after cataract surgery.
Can J Ophthalmol. 2008 Dec; 43(6): 712-6
Unal M, Yücel I
Background: An increase in intraocular pressure (IOP) frequently occurs after otherwise uneventful phacoemulsification cataract surgery. This study was conducted to determine the efficacy of bimatoprost 0.03% drops given preoperatively in preventing IOP rise following phacoemulsification cataract surgery.Methods: In this prospective, randomized, double-masked, placebo-controlled study, 91 eyes of 85 patients scheduled to have clear corneal phacoemulsification cataract surgery were randomly divided into 2 groups. One hour before surgery, 1 group (48 eyes) received 1 drop of bimatoprost 0.03%, and the other group (43 eyes) received 1 drop of a balanced saline solution (placebo). A masked observer measured IOP preoperatively, and 3 and 24 hours postoperatively. Anterior chamber cellular reaction was measured on the first day after surgery. Preoperative and postoperative central corneal thickness (CCT) was assessed.Results: The mean IOP changes from baseline were not statistically different between the 2 groups at 3 hours (p = 0.618). At 24 hours, there was a statistically significant difference between the mean IOP changes of the groups (p = 0.001). The incidence of IOP elevation greater than 5 or 10 mm Hg at 24 hours was significantly higher in the control group (9 of 43 eyes) than the bimatoprost group (3 of 48 eyes) (p = 0.039). Anterior chamber reaction was not increased by bimatoprost. Mean CCT change was not different between the groups at 24 hours (p = 0.615).Interpretation: When compared with placebo, prophylactic use of 1 drop of bimatoprost before phacoemulsification cataract surgery failed to produce a significantly different effect on IOP levels from placebo at 3 hours postoperatively, but it caused a significant IOP reduction at 24 hours.
Br J Ophthalmol. 2008 Nov 19;
Honrubia F, Garcia-Sánchez J, Polo V, Martinez-de-la-Casa JM, Soto J
AIM: To conduct a meta-analysis of randomized clinical trials (RCTs) in order to evaluate the development of conjunctival hyperemia after the use of latanoprost versus travoprost and bimatoprost, in patients with ocular hypertension or glaucoma. METHODS: In order to identify the potentially relevant RCTs, a systematic literature retrieval was conducted in Medline, Embase and Cochrane Controlled Trials Register (1995-April 2007) databases The outcome measure was the appearance of conjunctival hyperemia during the study. Statistical analyses included the calculation of odds ratio (OR) and its respective confidence interval, along with inter-trial statistical heterogeneity. Publication bias was evaluated through a funnel plot and a sensitivity analysis was also performed. RESULTS: In total, 13 RCTs involving 2,222 patients with ocular hypertension or glaucoma were included, 5 comparing latanoprost versus travoprost, 7 comparing latanoprost versus bimatoprost and 1 comparing latanoprost versus travoprost and bimatoprost. The combined results showed that latanoprost produced lower occurrance of conjunctival hyperemia than both travoprost (OR = 0.51; 95 % CI: 0.39-0.67, p < 0.0001) and bimatoprost (OR = 0.32; 95 % CI: 0.24-0.42, p < 0.0001). No significant heterogeneity was found between the included RCTs. There was no evidence of publication bias. In the sensitivity analysis performed, none of clinical trials included in this meta-analysis has an important impact in the global estimation of OR. CONCLUSIONS: According to available data, the use of latanoprost is associated with a lower incidence of conjunctival hyperemia when compared to travoprost and bimatoprost in the treatment of patients with ocular hypertension or glaucoma.
Prostanoids for the management of glaucoma.
Expert Opin Drug Saf. 2008 Nov; 7(6): 801-8
Arranz-Marquez E, Teus MA
BACKGROUND: Prostanoids are the newest pharmacologic group of ocular hypotensive drugs for clinical management of glaucoma. The group includes four chemical compounds structurally derived from naturally-occurring prostaglandin (PG) F(2). Prostanoids have been divided into PG analogues (unoprostone, latanoprost and travoprost) and prostamides (bimatoprost) because of differences in molecular structures. The drugs share a novel mechanism of action that produces a potent ocular hypotensive effect and a novel local adverse effect of increased iridial pigmentation. OBJECTIVE: To summarise the pharmacologic and clinical data regarding the effectiveness and safety of prostanoids in clinical glaucoma management. METHODS: The review was supported by a literature search of peer-reviewed publications, based on medical information available in databases such as PubMed. RESULTS/CONCLUSION: The prostanoids began a treatment revolution not only because of their novel mechanism of action but also as a result of a new local side effect.
Can J Ophthalmol. 2008 Oct; 43(5): 563-6
Yeom HY, Hong S, Kim SS, Kim CY, Seong GJ
BACKGROUND: In light of concern about the possible relation between the extensive clinical use of prostaglandin analogues and the development of retinal disorders such as cystoid macular edema, this study investigated the influence of topical application of bimatoprost 0.03% on macular thickness and volume in glaucoma patients with phakic eyes. METHODS: A total of 40 eyes in 22 patients with primary open-angle glaucoma or normal-tension glaucoma were evaluated in this study. Optical coherence tomography images were taken before initiation of bimatoprost application and after 1, 2, and 3 months of treatment. In addition, best-corrected visual acuity (BCVA) and intraocular pressure (IOP) were measured, and contrast sensitivity tests and fundus examinations were performed. Changes in various parameters, including macular thickness and volume, were analyzed. RESULTS: BCVA and contrast sensitivity did not change from baseline over the treatment period. IOP declined by 20% to 25% from baseline for 1 month before stabilizing. Macular thickness and volume did not increase significantly during the 3 months. INTERPRETATION: Topical application of bimatoprost does not induce clinical or structural changes in the macula, at least in glaucoma patients with phakic eyes. Moreover, bimatoprost effectively lowered IOP without causing macular disorders such as cystoid macular edema.
Effects of oxidative stress in trabecular meshwork cells are reduced by prostaglandin analogues.
Invest Ophthalmol Vis Sci. 2008 Nov; 49(11): 4872-80
Yu AL, Fuchshofer R, Kampik A, Welge-Lüssen U
PURPOSE: The trabecular meshwork (TM) of glaucomatous eyes is characterized by cell loss, increased accumulation of extracellular matrix (ECM), and cellular senescence. One factor increasingly discussed in the pathogenesis of primary open-angle glaucoma (POAG) is oxidative stress. The goal of this study was to determine whether oxidative stress is able to trigger these typical glaucomatous changes in vitro and whether these oxidative stress-induced TM changes can be reduced by the application of prostaglandin analogues. METHODS: Cultured human TM cells were exposed to 200 to 800 microM hydrogen peroxide (H(2)O(2)) for 1 hour. Cell loss was detected by cell-viability assay. Levels of fibronectin and MMP-2 mRNA were determined by real-time PCR analysis. Senescence-associated beta-galactosidase (SA-beta-Gal) activity was investigated by histochemical staining. The effects of prostaglandin analogues and benzalkonium chloride (BAC) on these glaucoma typical TM changes were investigated by preincubation of nonstressed or H(2)O(2)-treated cells with 1:100 diluted commercial solutions of bimatoprost, travoprost, and latanoprost or their corresponding BAC concentrations. RESULTS: H(2)O(2) induced cell death and fibronectin mRNA expression, but decreased the amount of MMP-2 mRNA. H(2)O(2) increased SA-beta-Gal activity. Additional pretreatment with BAC further increased the typical glaucomatous TM changes in vitro. These effects were reduced by preincubation with prostaglandin analogues in H(2)O(2)-treated and, to a lesser extent, in nonstressed cells. No reduction occurred in the presence of prostaglandin F receptor antagonists in H(2)O(2)-treated cells. CONCLUSIONS: Oxidative stress is able to induce characteristic glaucomatous TM changes in vitro, and these oxidative stress-induced TM changes can be minimized by the use of prostaglandin analogues. Thus, prevention of oxidative stress exposure to the TM may help to reduce the progression of POAG.
[Cost-efficacy analysis of fixed combinations of prostaglandin/prostamide for treating glaucoma.]
Arch Soc Esp Oftalmol. 2008 Oct; 83(10): 595-600
Martínez A, Slof J
OBJECTIVE: To assess the cost-efficacy of three fixed-combination glaucoma treatments currently available in Spain [bimatoprost with timolol (BT)- Ganfort(R), latanoprost with timolol (LT)- Xalacom(R), and travoprost with timolol (TT)- DuoTrav(R)]. METHODS: Because no studies are available that give a direct comparison of these drugs, a systematic review was carried out to assess their efficacy. Resource consumption and costs were estimated using a model of usual local practice. For each of the three drugs, average and incremental cost-efficacy ratios were determined in terms of euros per percentage point of reduction of intraocular pressure (IOP) over a three-month period. RESULTS: BT reduced IOP by 35.1%, LT by 35.0% and TT by 34.7%. Average cost-efficacy was estimated to be euro 5.34 per percentage point of IOP reduction with BT, euro 5.40 with LT, and euro 5.45 with TT. Incremental cost-efficacy (incremental cost per incremental percentage point of IOP reduction) was estimated to be euro 94.65 for LT vs. TT, and was negative for BT vs. TT and BT vs. LT, since in both cases BT was more efficacious and less expensive. CONCLUSIONS: Compared to travoprost/timolol and latanoprost/timolol, bimatoprost/timolol appears to be the most economic alternative, with equal or better efficacy and safety results (Arch Soc Esp Oftalmol 2008; 83: 595-600).
J Ocul Pharmacol Ther. 2008 Oct; 24(5): 517-20
Sonty S, Donthamsetti V, Vangipuram G, Ahmad A
PURPOSE: The aim of this study was to study long-term intraocular pressure (IOP) lowering following a switch to bimatoprost in patients with open-angle glaucoma (OAG) not at target IOP while on latanoprost either as monotherapy or as polytherapy with other topical adjunctive agents. METHODS: A retrospective review of OAG patients, with
Cesk Slov Oftalmol. 2008 Jul; 64(4): 144-8
Skorkovská K
AIM: To compare intraocular pressure (IOP) lowering efficacy of bimatoprost 0.03% / timolol 0.5% fixed combination (BTFC) and other combinations of glaucoma drugs (bimatoprost, latanoprost 0.005% / timolol 0.5% fixed combination, separate use of travoprost 0.004 % and timolol 0.5 %) in patients with glaucoma. PATIENTS AND METHODS: Fifty-three patients with glaucoma were divided into 3 groups according to their original glaucoma therapy. BTFC was used by the patients for a period of 3 months. After 1 week, 1, 2 and 3 months, the diurnal IOP curves were performed. Side effects of the new treatment were recorded and compared to the original therapy. RESULTS: The mean diurnal IOP reduction in the group of patients switching from bimatoprost to BTFK reached 4.4 +/- 2.28 mm Hg (p < 0.01). In the group of patients initially on latanoprost / timolol fixed combination, the IOP decreased with BTFK by 2.3 +/- 1.5 mm Hg (p < 0.01). Changing therapy from travoprost / timolol seperate combination to BTFK caused an IOP decrease by 2.3 +/- 1.5 mm Hg on average (p < 0.01). Conjunctival hyperemia with initial therapy was experienced in 33% of patients in our study group. With BTFK application, the hyperemia improved in 69% of these patients, got worse in 12.5% and remained unchanged in 19% of the patients. Patients found the BTFK better than the original medication in 37.5% of cases, the same in 52% and worse in 10.5%. Five patients terminated the study earlier due to poor IOP compensation or marked side effects of BTFK. CONCLUSION: In all three groups of glaucoma patients there was a significant and prolonged decrease in IOP after treatment with BTFK. The use of BTFK was accompanied by smaller incidence of conjunctival hyperemia compared to isolated bimatoprost or travoprost / timolol combination.